Choosing a Bioanalytical CRO: Fit, Milestones & Pitfalls

Q: How long from first inquiry to first sample run?

The quote lands within two business days. From approval, development typically takes two to four weeks and GLP validation two to three on LC-MS/MS, so a new-method regulated study is commonly running samples inside six to eight weeks. Your calendar is committed at kickoff, not discovered later.

Q: What do you need from us to quote accurately?

Molecule and class, matrix and species, the regulatory tier, any existing method with its conditions and recent data, and cohort counts if you have them. Partial is fine: step three of the map exists to close the gaps before the number is set, which is why the number then holds.

Q: What quiet pitfalls should we check any lab for?

Method transfers priced as if nothing ever fails to transfer, per-run pricing that meters your budget batch by batch, no named scientist in the paperwork, and a quote silent on what happens when scope moves. Ask any lab, including us; we have put our answers in writing.

Q: Can we start before the protocol is final?

Yes, and it is often smarter: method development and feasibility can run from a synopsis while the protocol finalizes, so validation is ready when the study is. The scope makes the boundary explicit, and nothing regulated runs ahead of the paperwork.

Q: Who is our point of contact through all eleven steps?

The senior scientist on your method, with a project manager keeping the calendar and the QAU auditing independently. The names you meet at step five are the names on the final report; that continuity is most of what sponsors mean when they say the process worked.

Need The Calendar Before You Commit?

Step-by-step dates and an itemized quote, back in two business days.

Your Method, Data And Requirements Reviewed Up Front, Before Anyone Quotes Anything
Senior Scientists In The Conversation From First Call To Final Report, Same Names Throughout
Single-Analyte Validation In 2-3 Weeks, Cohorts In 1-2 Each, The Audited Report In About 2, All In Writing
Seven Hidden Pitfalls, From Unsecured Assay Supplies To Late Biomarker Planning, Screened In Your First Review

“NorthEast BioLab always exceeds expectations on bioanalytical assay development, validation, and sample analysis.”

VP, PK PD Analysis

Regulated And Inspected By:

What Your Bioanalytical Calendar Holds

2 Days To An Itemized Quote

11 Steps To Audited Report

2-3 Weeks, NCA From Locked Data

~2 Weeks To Audited Report

How Your Study Moves Through Our Bioanalytical Lab, Step By Step

The map never changes; only the assay does. Every step is deliberate, which is the difference between doing it right and just doing it.

Customer inquiry
Your study lands, a business development executive replies within one business day, and a scientist reads it before your first call; the conversation starts with science, not a sales script.
Fit evaluation
We say no early when the lab is wrong for the work; a fast no protects your timeline and our record. Fit is decided on the first call.
Preliminary consulting
Method, preliminary data, regulatory requirements and supply sources reviewed before anyone talks price.
Quotation
An itemized quote within two business days, fixed. Pricing moves only when you sign a scope change.
Project initiation
Named scientists, project manager and QA on one kickoff call; you meet people, not a distribution list. Kickoff lands the same week your signed quote does.
Method development
Typically two to four weeks depending on molecule and matrix, with the reasoning documented, not just the settings.
Method validation
GLP LC-MS/MS in about two to three weeks, ligand binding four to six, run against FDA and ICH M10 expectations.
Sample measurement
Cohorts return in one to two weeks each against an agreed calendar, with incurred sample reanalysis on regulated studies.
PK / biomarker evaluation
PK parameters in WinNonlin, with NCA back in two to three weeks from a locked dataset. Biomarker correlations where the study calls for them, and we deliver the PC and PP domains, SEND and SDTM, ready for eCTD.
Audited report
The independent QAU audits data and report before anything leaves; the audited report follows completion in about two weeks.
Next steps
Methods live here for the life of your program: the next study starts from a running method, not from scratch.

What Each Milestone Delivers

A named document lands in your inbox at every step; silence is never the status.

The Deliverables, Named

ScopingA written scope and an itemized quote.

DevelopmentA development summary that documents the reasoning, not just the settings.

ValidationA QAU-audited validation report written against FDA and ICH M10.

Sample analysisBatch data packages per cohort with chain-of-custody records, ISR summaries on regulated studies, and running status you never have to chase.

PK analysisWinNonlin outputs with the PC and PP domains delivered, SEND and SDTM, ready for eCTD.

Study closeThe audited final report plus, on request, the assembled data package your auditors will someday ask for, ready before they do.

When A Batch Fails

Batches fail sometimes in bioanalysis. What matters is the machinery that catches them.

Principal investigator on your method calls with the finding and the new date.
Full detail alongside the data, in the report your auditors read.
ISR failure opens an investigation under the eQMS before more data is reported.

Awarding Your Study? Let's Check Bioanalytical Plan.

Describe the study; we flag the typical pitfalls before you sign.

Your First Bioanalysis Study, In Plain Terms

First-time sponsors, NIH and SBIR grantees among them, run studies here every year. The vocabulary is simpler than it looks.

GLP or non-GLP

Discovery and screening run non-GLP, lighter and faster. Anything heading toward an IND runs GLP, with full validation and an audited report. We run both and tell you which your stage needs.

What an IND needs from bioanalysis

Validated methods, GLP sample analysis and reports an agency can read. That package is this lab’s standing work, IND-enabling studies included.

What moves cost

The number of analytes, the matrix, the regulatory tier, the sample count, and whether a validated method already exists. Tell us those five and an itemized quote comes back in two business days.

Grant-funded work

We write letters of support for grant applications. Representative work includes first-in-human CNS PK in plasma, urine and CSF, with data back before each dose escalation.

The Seven Bioanalytical Pitfalls Sponsors Find Too Late

Each one is visible in a quote and we show you where to look; we design against all seven.

Unsecured assay supplies
Reference standards, anti-ID antibodies, antigens, primers and labelled internal standards are long-lead items. We lock critical reagents and commercial kits at scoping, so a backorder never stalls a validated method.
An assay never optimized for your species and matrix
Platform choice, collection and shipping methodology, calibration range and dilution linearity get set against your actual samples, so data does not die by BLQ, ALQ or hook-effect reassays.
Partial validation on a GLP or GCP study
Precision and accuracy, sensitivity, specificity, selectivity, spike recovery, parallelism and stability, completed in the specific sample rather than assumed from a kit insert.
Efficacy first, IND-enabling studies last
Safety and toxicity PK, biodistribution and ADA are sequenced against the therapeutic index, route and regimen, so the filing package is not rebuilt at the end.
Biomarkers and secondary endpoints left for the very end
PK and biodistribution, ADA and NAb, cytokine profiling and gene expression are planned into the protocol, not bolted on after the database locks.
Sample logistics ignored until samples move
Site kits and equipment, collection, processing and shipment protocols, reconciliation and long-term storage, managed end to end under one chain of custody.
The lab itself unvetted
Turnaround, pricing mechanics, sponsor visibility and an agency-inspection record are all checkable before you award. Check them on every lab, including us.

What Sponsors Say About The Process, Verbatim

Quoted with permission, names withheld. Yours would be too.

Got Another Bioanalytical CRO Quote? Tell Us More.

We tell you what it leaves out.

VP, Bioanalytical Development
★★★★★
NorthEast BioLab is the most responsive and thorough bioanalysis lab services CRO.
Director, PK
★★★★★
We worked closely to implement the most efficient and cost-effective bioanalytical assay for our PK Studies.
Dir., Bioequivalence Testing
★★★★★
Our latest successful study was a pivotal bioequivalence study, where samples from a cross-over study with about 100 volunteers needed swift analysis.
Head, PK
★★★★★
This study, same as all other bioanalytical studies, was completed with top quality and reporting standard with incredible responsiveness.
Head, Bioanalytical Development
★★★★★
NorthEast BioLab goes the extra mile. We look forward to more meaningful collaborations.
VP, Head of Clinical Operations
★★★★★
Our projects with NorthEast BioLab include successful method development, validation, stability studies during Clinical Phase I-IV studies.